The À1p/À19q genotype predicts chemosensitivity in oligodendroglial neoplasms, but some with intact 1p/19q also respond and not all with 1p/19q loss derive durable benefit from chemotherapy. We have evaluated the predictive and prognostic significance of pretherapy 201 Tl and 18 F-FDG SPECT and genotype in 38 primary and 10 recurrent oligodendroglial neoplasms following PCV chemotherapy. 1p/19q loss was seen in 8/15 OII, 6/15 OAII, 7/7 OIII, 3/11 OAIII and was associated with response (FisherExact: P ¼ 0.000) and prolonged progression-free (log-rank: P ¼ 0.002) and overall survival (OS) (log-rank: P ¼ 0.0048 Tl P ¼ 0.0132). 201 Tl uptake and 1p/19q loss were independent predictors of survival in multivariate analysis. In this initial study, 201 Tl and 18 F-FDG uptake did not predict response to PCV, but may be associated with poor survival following therapy irrespective of genotype. This may be clinically useful warranting further study.
Oligodendroglial neoplasms with the À1p/À19q genotype have a more indolent clinical evolution, are associated with prolonged survival and are more likely to be chemosensitive than their morphologically equivalent counterparts with intact 1p/19q (Cairncross et al, 1998; Smith et al, 2000; van den Bent, 2004) . The biological basis behind these clinical differences are not yet well understood, but are likely to result from complex interactions between tumour genetics and host environment, as well as physiological factors that determine drug delivery Hartmann et al, 2004; Jeuken et al, 2004) . Genotype and factors such as blood flow or blood volume and metabolism have been associated with chemoresponsiveness in anaplastic oligodendrogliomas (Warnke, 1998; Engelhard et al, 2003; Jager et al, 2005) . Despite responsiveness to therapy, oligodendroglial neoplasms with the À1p/À19q genotype inevitably recur, sometimes with only short progression-free survival (PFS). Prognostic or predictive factors that may be used to identify patients likely to derive durable clinical benefit are therefore essential.
Metabolic imaging using radiolabeled tracers such as 201 Thallium or 18 F-fluorodeoxyglucose has been used in a number of glioma studies, to yield diagnostic or prognostic information (Benard et al, 2003; Padma et al, 2003; Datta et al, 2004) , to guide biopsy (Levivier et al, 2002) , to distinguish recurrent tumour from radiation necrosis (Stokkel et al, 1999) or monitor response to therapy (Vos et al, 2003) but the relationship between metabolism and chemosensitivity in oligodendroglial neoplasms has still to be determined. In a multidisciplinary study of oligodendroglial neoplasms undergoing therapy at a single UK treatment centre between 2000 and 2003, the À1p/À19q genotype was associated with a more indolent clinical history with longer time to first oncology therapy and prolonged survival from first referral, than cases with intact 1p/19q . Response and favourable outcome following procarbazine, lomustine and vincristine (PCV) chemotherapy was strongly associated with the À1p/À19q genotype (Walker et al, 2006) . No relationship was observed between pretherapy single-voxel Magnetic Resonance Spectroscopy and genotype (Jenkinson et al, 2005) . In contrast, pretherapy brain Single-Photon Emission Computed Tomography (SPECT) data revealed that tumours with 1p/19q loss were more likely to show increased 201 thallium uptake and to a lesser degree, 18 F-fluorodeoxyglucose uptake than those without these losses (Walker et al, 2004) .
The aim of the present study was to determine whether pre-therapy 201 Tl or 18 F-FDG SPECT may be used to predict therapeutic response and outcome in oligodendroglial neoplasms treated with PCV chemotherapy and to compare this with genotype.
PATIENTS AND METHODS

Case selection and pathology
Cases for investigation were from a prospective study of adult oligodendroglial tumours at the Walton Centre for Neurology and Neurosurgery/Clatterbridge Center for Oncology diagnosed between May 2000 and July 2003 . For inclusion in this study, patients had pathology diagnosis and SPECT data pretherapy, were treated by PCV chemotherapy and gave research consent. Cases in this study were included in larger series reporting pretherapy associations between SPECT data, genotype and histopathology (n ¼ 59) (Walker et al, 2004) and between genotype and response to PCV chemotherapy (n ¼ 76) (Walker et al, 2006) . The study had local ethics committee approval. Consensus pathological diagnosis and grading according to current WHO criteria (Kleihues and Cavanee, 2000) was undertaken by two consultant neuropathologists. The study included 38 previously untreated patients (11 oligodendroglioma WHO grade II (OII), 14 oligoastrocytoma WHO grade II (OAII), five oligodendroglioma WHO grade III (OIII), eight oligoastrocytoma WHO grade III (OAIII)) and 10 with tumours that recurred following previous radiotherapy (four OII, one OAII, two OIII, three OAIII). The median time between previous radiotherapy and metabolic imaging was 5.7 years (range 1.1-13.9 years). The median age was 43 (range 27-71). All patients had surgery prior to therapy. In all, 94% had biopsy only (three image-guided, 42 serial-stereotactic). Three patients had a partial resection with residual tumour clearly assessable on MRI postsurgery and before nuclear medicine imaging.
201
Tl SPECT and 18
F-FDG imaging
Nuclear medicine imaging was post surgery and pretherapy for 47 patients. One patient had imaging before biopsy and therapy. The median time from surgery to imaging was 19 days (range À21 -301 days); 98% had imaging within 2 months of surgery. All cases had tumour clearly visible on MR or CT at the time of imaging with cross sectional area 410 cm 2 (median 30 cm 2 (range 10 -74 cm 2 )).
201
Thallium ( 201 Tl) SPECT and 18 F-2-Fluoro-2-deoxy-D-glucose ( 18 F-FDG) SPECT scans were obtained using a dual headed collimated gamma camera (DSTXL GESMVI, 1998) . Images were acquired, reconstructed and reported using standard protocols as described previously (Walker et al, 2004) . The spatial resolution of SPECT was 5 mm. 18 F-FDG uptake was assessed as hypermetabolic or hypometabolic, if the intensity of signal within the known site of tumour was greater than or less than the equivalent site in the contralateral hemisphere, respectively. Similarly, scans were reported as having either increased or normal 201 Tl uptake at the site of the tumour compared with the contralateral hemisphere. Semiquantitative data was obtained as described previously (Walker et al, 2004) . Reconstructed transverse slices in interfile format were imported into NIH Image (http://rsb.info.nih.gov/ nih-image). The tumour was located by comparison with MR or CT images and regions of interest (ROI) that delineated the part of tumour with the greatest difference in signal intensity and representative of the most aggressive biology were drawn. Uptake of 201 Tl or 18 F-FDG was measured in an axial slice containing the selected ROI and expressed as the ratio of the mean tumour counts in the ROI and the mean activity in an equivalent ROI mirrored in the contralateral hemisphere.
18 Tl SPECT data reported as hypermetabolic or increased had uptake relative to the contralateral brain of 40.9 and 41.1, respectively. Postsurgery and pretherapy 201 Tl SPECT data was available for 46 patients and 18 F-FDG SPECT for 48 patients.
Chemotherapy
Chemotherapy followed nuclear medicine imaging, with median time interval 19 days (range 2 -152 days); 92% had therapy within 2 months of imaging. PCV chemotherapy was administered according to standard clinical protocols (Levin et al, 1980) . Lomustine (CCNU) (110 mg m À2 ), procarbazine (60 mg m À2 ) and vincristine (1.4 mg m À2 (maximum 2 mg)) were given on Days 1, 8 -21 and 8 and 29, respectively. Cycles were repeated every 6 weeks for a maximum of six cycles. The median pretherapy performance status, assessed using the ECOG scale, was 1 (range 0 -4). Two high-grade cases died before completing the first cycle, the remainder received a median of four cycles with 33% completing six cycles. PCV was discontinued after cycle 1 in three cases, and treatment continued with temozolomide (2) or radiotherapy (1).
Response assessment
Response was assessed as described previously (Walker et al, 2006) . A consultant neuroradiologist reviewed all available MR or CT images taken before, during and after chemotherapy, and at follow-up without knowledge of SPECT data, genotype or other clinical factors. The largest perpendicular diameters of the tumour were measured in axial sections of contrast-enhanced regions of T1-weighted MR or CT images or T2-weighted MR images. In 31 enhancing cases, response was assessed using Macdonald criteria (Macdonald et al, 1990) . Response categories were: -CR-complete response (disappearance of all tumour, off steroids and neurologically stable or improved); PR -partial response (50% or greater reduction in cross-sectional area, steroids stable or reduced, and neurologically stable or improved); PD -progressive disease (25% or greater increase in cross sectional area or any new tumour on CT/MR images and/or neurologically worse with steroids stable or increased); SD -stable disease (all other situations). In 10 nonenhancing cases and three for whom contrast enhancement was not assessable, response was assessed using T2-weighted images (Hoang-Xuan et al, 2004; Stege et al, 2005 ). An additional minor response (MR) category (425 -o50% reduction in cross-sectional area, steroids stable or reduced, and neurologically stable or improved) was included, as some cases showed radiological reduction in cross sectional T2W area of 425 -o50%, accompanied by clinical benefit. None of the enhancing cases had radiological changes in this range. Response was not assessed due to early death (two cases) or insufficient imaging data (two cases).
Clinical information
Information regarding current management, follow-up and outcome was collected prospectively. Progression-free survival and OS were calculated from the start of PCV. The median follow-up time was 25 months (range 1 -57) from start of chemotherapy and 40 months (range 16 -57) for the 28 patients alive at study.
Molecular genetics
For each case regions of tumour histology in pretherapy resected tumours or biopsy specimens representative of the most aggressive tissue available and the overall pathology diagnosis were selected for study. Laser capture microdissection was used to enrich the tumour component in the samples for analysis and determination of allelic imbalance was carried out using paired normal and tumour samples and multiple simultaneous PCR amplification of a panel of microsatellite markers, followed by capillary electrophoresis and data analysis as described previously (Walker et al, 2003 (Walker et al, , 2004 . The microsatellite panel included: chromosome 1-D1S2667, D1S508, D1S214 (1p36); chromosome 19-D19S412, D19S112, D19S596 (19q13) . Additional markers, D1S468, D1S2795 (1p36) and D19S217, D19S572 (19q13) were used for cases that lacked informativity for given loci.
Statistics
Statistical analysis was performed using SPSS. The Mann -Whitney test was used for non-normally distributed SPECT data and w 2 or Fisher's Exact tests were used for categorical data. Kaplan -Meier survival curves were obtained and differences in PFS or OS were tested for statistical significance using the log-rank test. Univariate and multivariate analysis was used to determine if genotype, 201 Tl and 18 F-FDG uptake, gender, age, ECOG status, histopathology grade and subtype, contrast enhancement, therapy for primary or recurrent tumour had prognostic significance with respect to survival. Cox Regression multivariate analysis for factors significantly associated with survival in univariate analysis was by forward stepwise entry of parameters at a significance of 0.05 for entry and 0.01 for removal. P-values (two-tailed) o0.05 -0.01 were considered weakly significant and those o0.01 of greater significance.
RESULTS
SPECT data, histopathology and genotype
Associations of SPECT data with histopathology and genotype have been reported previously in a larger series (Walker et al, 2004) . In this subgroup of the original series, loss of 1p36 and 19q13 was found in 8/15 OII, 6/15 OAII, 7/7 OIII, 3/11 OAIII and associations of SPECT data with genotype and histopathology grade are given in Table 1 
Response
Response, assessed in 44 cases given 41 cycle of chemotherapy (41 PCV, two PCV þ temozolomide, one PCV þ xrt), was signifi- Tl uptake and the median and range for each group. P -probability calculated using * w 2 test; B Mann -Whitney test. Weakly significant P values are given in italics; those of greater significance are given in bold. Response data is given for the series as well as in subgroups according to therapy given to primary or recurrent tumour, histopathology grade, genotype and response assessment based on enhancing tumour or T2-weighted MR. Data shows the proportion of responding cases in each group; data given as number of cases showing response that is (CR+PR+MR)/number of cases and (%). P -probability calculated using Fisher's exact test. Weakly significant P values are given in italics; those of greater significance are given in bold.
cantly associated with combined loss of 1p36 and 19q13, but 7/22 (32%) with intact 1p36 and 19q13 also responded ( (Figure 1 ). In cases with intact 1p/19q all responders and 9/14 nonresponders had 201 Tl uptake p1 and five nonresponders (four recurrent tumours which showed PD and one primary tumour with SD) had increased 201 Tl uptake (Figure 1 ). This resulted in a statistically significant difference in 201 Tl uptake between responders and nonresponders in tumours with intact 1p/19q, which was not seen in categorical analysis (Table 2) .
Survival
To compare the prognostic significance of metabolism with that of genotype, Kaplan -Meier plots for PFS and OS following PCV chemotherapy are given in Figure 2 Tl uptake enabled significant prognostic discrimination for PFS in cases with or without the À1p/À19q genotype, but for OS only in cases with intact 1p36 and 19q13 (Figure 3 ). Similar findings were observed if only primary cases were analysed (Supplementary Data).
201
Tl uptake was an independent prognostic factor for PFS and OS in multivariate analysis in cases with intact 1p/19q (Cox Regression: PFS-HR 7.0 (95% CI 1.9 -25.5), P ¼ 0.003; OS-HR 9.1 (95% CI 2.2 -37.9), P ¼ 0.002).
Of the 27 cases that responded to therapy, 10 had 18 F-FDG hypermetabolism and 12 had increased 201 Tl uptake and elevated metabolism was significantly associated with short PFS (log-rank PFS:
18 F-FDG P ¼ 0.005; 201 Tl P ¼ 0.0132).
DISCUSSION
Although the association between 201 Tl and 18 F-FDG uptake and adverse prognosis has been reported previously in gliomas (Higa et al, 2001; Benard et al, 2003; Padma et al, 2003; Comte et al, 2006) , this study represents the largest series of oligodendroglial neoplasms with response and outcome data following treatment by a uniform chemotherapeutic protocol, and is the only study to investigate metabolism and outcome in oligodendroglial neoplasms classified by molecular genetics. The cohort was drawn from a larger study of oligodendroglial neoplasms from a single treatment centre over a 3-year period (Walker et al, , 2006 and reflects the range of patients with histopathological diagnosis of oligodendroglial tumour given PCV chemotherapy in the routine clinic. Associations of genotype with response and outcome in this subgroup compared well with the larger series that included 490% of oligodendroglial neoplasms given PCV in the study period (Walker et al, 2006) . Previously we have shown that elevated metabolism is associated with 1p/19q loss, as well as with increased histopathological grade (Walker et al, 2004) . Elevated metabolism was significantly more common in low-grade tumours with 1p/19q loss than in those with intact 1p/19q (Walker et al, 2004) . These findings remained valid for 201 Tl SPECT in the subset treated by PCV chemotherapy, but significant associations between genotype and 18 F-FDG, which were weaker than 201 Tl in the previous report, were not observed in this subset, due to the lower numbers and reduced statistical power. As in the previous study, increased uptake of both Tl in low-grade cases was found only in those with 1p/19q loss. The study included primary tumours given PCV as first oncology therapy as well as those receiving PCV following recurrence after radiotherapy, reflecting clinical practice. The recurrent group had a higher proportion of cases with grade III pathology and was more likely to show increased 201 Tl uptake than primary cases. However, only 10 recurrent cases were investigated and as gliomas progress with time, they are likely to recur as a more aggressive tumour, which would be reflected in their metabolism. Further study in larger series would be necessary to explore metabolic differences between primary and recurrent tumours.
It has been suggested that increased metabolism may be related to therapeutic responsiveness to alkylating agents as these should exert a more beneficial effect in tumours with higher cell turnover and DNA-synthesis rates, which are known to correlate with higher glucose utilisation and metabolism (Herholz et al, 1993; Brock Tl uptake. Numbers in each group indicated in parentheses. P-Probabilities calculated by the log-rank test. Cox regression analysis for PFS and OS (n ¼ 46) comparing SPECT data and genotype with significant clinicopathological factors. Histological subtype, presence or absence of contrast enhancement, age and ECOG status were not significantly associated with outcome in this cohort. Data given as the hazard ratio (HR) relative to baseline (*) and 95% confidence interval. NS -not significant in univariate analysis. P-Probability; R-term removed. Weakly significant P values are given in italics; those of greater significance are given in bold.
et al, 2000; Prados, 2000) . The methods for assessing response used in this study are widely utilised for gliomas, despite their limitations (Perry and Cairncross, 2003) . As in other studies, response was strongly associated with the À1p/À19q genotype (Cairncross et al, 1998; Ino et al, 2001; van den Bent, 2004) . Tumours with or without features of elevated metabolism showed response following PCV chemotherapy. Elevated metabolism was not necessary for response and no associations with response were evident in the series as a whole or subdivisions according to grade, enhancement, or therapy given to primary or recurrent tumours. When subdivided by genotype, significant associations were only seen on analysis of semiquantitative data in cases with intact 1p/ 19q, where 201 Tl uptake was greater in nonresponders. However, 64% of these had normal 201 Tl uptake and significant differences were not obtained in categorical analysis. Further study of a larger series would be necessary to resolve this discrepancy. In the series overall, response was strongly associated with the À1p/À19q genotype, but not metabolism, suggesting that genetic lineage is dominant over metabolism in influencing chemosensitivity. Metabolism measured by 201 Tl or 18 F-FDG uptake is not a useful noninvasive diagnostic procedure to predict chemosensitivity in the absence of knowledge of genotype.
Although tumours with the À1p/À19q genotype are likely to respond to chemotherapy, all oligodendroglial neoplasms inevitably recur, with wide variations in PFS even in those with the À1p/À19q genotype (van den Bent, 2004) . In addition, a significant proportion of oligodendroglial neoplasms with intact 1p/19q may be chemosensitive, albeit associated with shorter PFS than those with 1p/19q loss (Ino et al, 2001; van den Bent et al, 2003; Walker et al, 2006) . Identification of factors that enable prognostic stratification, would permit more effective clinical management and provision of chemotherapy to patients for which it may be of lasting benefit. In the present study, elevated 201 Tl and 18 F-FDG uptake were both significantly associated with shorter PFS, in the series, in separate analysis of cases with or without the À1p/À19q genotype and in cases that responded to therapy.
201 Tl uptake was an independent prognostic variable in multivariate survival analysis in the series and in cases with intact 1p/19q. These findings suggest that SPECT data may potentially be useful to predict cases for which chemotherapy may not be of long-term benefit and where additional therapy should be implemented early at the first signs of recurrence. However, the heterogeneity of the cohort is a limitation of the study. Primary and recurrent cases were included, although similar findings were obtained if primary cases only were considered. Oligodendrogliomas and oligoastrocytomas are both commonly treated by chemotherapy and their histopathological diagnosis is highly subjective and notoriously difficult. Classification by molecular genetics is now widely accepted (Reifenberger and Louis, 2003) . As in our larger series, the proportion of oligodendrogliomas with loss of 1p/19q (68%), was lower than reported in some studies, which may reflect diagnosis from small biopsies less prone to fixation artefact . Histopathological subtype was not associated with response or survival and elevated metabolism remained significantly associated with outcome after adjustment for histopathology subtype.
The most appropriate time to deliver therapy is a key question in the clinical management of patients that present with oligodendroglial neoplasms with low-grade pathology (van den Bent, 2004) . Conventional indicators of progression to a highgrade glioma include contrast enhancement and histopathology. However, histopathological grading relies on subjective judgment of morphological features and is frequently associated with interobserver variability (Giannini et al, 2001) , while contrast enhancement is also present in many low-grade oligodendroglial neoplasms White et al, 2005) . Elevated metabolism may also be considered an early indication of tumour progression (Higa et al, 2001; Benard et al, 2003; Padma et al, 2003; Vos et al, 2003; Datta et al, 2004) , and in this study was seen in both low-and high-grade tumours. However, too few grade II cases with elevated metabolism or grade III cases with normal metabolism were available to permit assessment of the prognostic significance of SPECT data separately in low or high-grade cases.
In keeping with the known associations of the À1p/À19q genotype with prolonged survival, cases with 1p/19q loss and elevated metabolism had longer PFS and OS than cases with intact 1p/19q and high metabolism. Intriguingly, these data suggest that there may be differences in the thresholds at which metabolism becomes associated with aggressive behaviour and/or differences in the baseline biology of oligodendrogliomas with or without the À1p/À19q genotype. However, further studies with more biological markers would be required to address this issue. Despite the limitations of the study and its small heterogeneous cohort, our findings show promise that metabolism may have prognostic significance irrespective of genotype. Confirmation in a larger more homogeneous series, particularly primary tumours, is therefore essential.
From a molecular genetic viewpoint, progression in gliomas is associated with sequential accumulation of genetic alterations with consequent deregulation of the cell cycle and increased angiogenesis (Hartmann et al, 2004; Jeuken et al, 2004) . Upregulation of angiogenesis factors and a variety of genetic alterations including deletion of CDKN2A, loss of chromosome 10, downregulation of ATase and cyclooxygenase-2 expression have been associated with progression and poor prognosis in oligodendroglial neoplasms (Jaeckle et al, 1998; Castilla et al, 2003; Hartmann et al, 2004; Jeuken et al, 2004) . While genetic analysis to determine the 1p/19q status may be introduced into routine diagnostic practice, no single test is presently available to indicate tumour progression and poor outcome. Features of elevated metabolism in this and other studies of oligodendrogliomas (Giammarile et al, 2004) or gliomas (Vos et al, 2003; Pardo et al, 2004) have been associated with poor prognosis and may result as a consequence of deregulation of signal transduction through a variety of genetic changes, rather than being associated with a single genetic event. These data suggest that, in addition to the 1p/19q status, metabolic scans may be potentially useful to predict prognosis and identify cases with short-term benefit from PCV. This may be of greatest utility in determining those cases with intact 1p/19q that will benefit from chemotherapy.
In this initial study, we have shown that elevated metabolism is not predictive of response to therapy, but may be associated with poor survival following therapy irrespective of genotype. Further confirmation in a larger series is therefore warranted.
